Supplemental Oxygen in Pulmonary Embolism (SO-PE)

Description

A study of how supplemental oxygen helps patients with acute pulmonary embolism (PE). Hypothesis: Oxygen affects right ventricular dysfunction (RVD) in patients with acute pulmonary embolism (PE) primarily by relieving hypoxic pulmonary vasoconstriction and reducing pulmonary pressure (PA) pressure, and that this process is metabolically driven.

Conditions

Pulmonary Embolism, Venous Thromboembolism, Metabolomics, Oxygen Inhalation Therapy

Talk to us

Study Overview

On this page

Study Details

Study overview

A study of how supplemental oxygen helps patients with acute pulmonary embolism (PE). Hypothesis: Oxygen affects right ventricular dysfunction (RVD) in patients with acute pulmonary embolism (PE) primarily by relieving hypoxic pulmonary vasoconstriction and reducing pulmonary pressure (PA) pressure, and that this process is metabolically driven.

Supplemental Oxygen in Pulmonary Embolism (SO-PE)

Supplemental Oxygen in Pulmonary Embolism (SO-PE)

Condition
Pulmonary Embolism
Intervention / Treatment

-

Contacts and Locations

Boston

Massachusetts General Hospital, Boston, Massachusetts, United States, 02114

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adults ≥18 years old
  • * Confirmed Pulmonary Embolism (PE) on computed tomography pulmonary angiography (CTPA) performed \<24 hours prior to enrollment
  • * Symptom duration \<72 hours
  • * Confirmation of right ventricular dysfunction (RVD) by clinician
  • * Oxygen saturation ≥90% while breathing room air
  • * Hemodynamic instability
  • * Use of vasopressors or mechanical circulatory support
  • * Planned use of thrombolytics or plan for embolectomy
  • * Oxygen saturation \<90% while breathing room air at any time in the Emergency Department (ED)
  • * New onset arrhythmia
  • * History of pulmonary hypertension, chronic obstructive pulmonary disease (COPD), hypoventilation syndrome, or congestive heart failure (CHF) with left ventricular ejection fraction \<40%
  • * Known pregnancy
  • * Use of chronic oxygen therapy at baseline
  • * Vasodilator medication used in the past 24 hours
  • * Symptom onset ≥72 hours
  • * Inability to wear a face mask
  • * Technically inadequate baseline echocardiogram
  • * Temperature \>39° C
  • * Positive test for Covid-19 or influenza within the previous 10 days

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Massachusetts General Hospital,

Christopher Kabrhel, MD, MPH, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

2027-06-30